

# Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

## Oncotator

RRID:SCR\_005183

Type: Tool

---

### Proper Citation

Oncotator (RRID:SCR\_005183)

---

### Resource Information

**URL:** <http://www.broadinstitute.org/cancer/cga/ncotator>

**Proper Citation:** Oncotator (RRID:SCR\_005183)

**Description:** A tool for annotating human genomic point mutations and indels with data relevant to cancer researchers. Genomic Annotations, Protein Annotations, and Cancer Annotations are aggregated from many resources. A standalone version of Oncotator is being developed.

**Abbreviations:** Oncotator

**Resource Type:** analysis service resource, data analysis service, production service resource, service resource

**Keywords:** annotate, genomic, point mutation, indel, mutation, genome, protein, variant

**Related Condition:** Cancer

**Resource Name:** Oncotator

**Resource ID:** SCR\_005183

**Alternate IDs:** OMICS\_00178

**Record Creation Time:** 20220129T080228+0000

**Record Last Update:** 20260821T042652+0000

---

### Ratings and Alerts

No rating or validation information has been found for Oncotator.

No alerts have been found for Oncotator.

## Data and Source Information

**Source:** [SciCrunch Registry](#)

## Usage and Citation Metrics

We found 223 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Camp SY, et al. (2026) Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss. Science advances, 12(8), eadv5457.

Kuo HH, et al. (2026) Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. Science advances, 12(26), eadz3351.

Ravillah D, et al. (2026) VSIG10L is a major determinant of esophageal homeostasis and inherited predisposition to Barrett's esophagus. Nature communications, 17(1).

Shi Y, et al. (2026) Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF-Mutant Melanoma. bioRxiv : the preprint server for biology.

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1835.

Feng J, et al. (2026) Molecular and clinical characteristics of glioma patients with germline pathogenic mutations of Lynch syndrome genes: a large-scale multicenter study. Journal of translational medicine, 24(1).

Yang W, et al. (2026) Clinically actionable stratification of uncommon MET fusions: a precision oncology framework. Journal of translational medicine, 24(1).

Gentile C, et al. (2026) mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion. bioRxiv : the preprint server for biology.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Cell reports. Medicine, 6(2), 101929.

Ghosh A, et al. (2025) Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours. Communications biology, 8(1), 207.

Zhong S, et al. (2025) Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine, 6(8), 102217.

K??bler K, et al. (2025) Tamoxifen induces PI3K activation in uterine cancer. *Nature genetics*, 57(9), 2192.

Liu Z, et al. (2025) Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications. *The oncologist*, 30(11).

Zhang X, et al. (2025) Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets. *Nature communications*, 16(1), 4398.

Feng EM, et al. (2025) Racial variation in the advanced prostate cancer genome. *Prostate cancer and prostatic diseases*, 28(4), 902.

Sun W, et al. (2025) A mutational process signature and genomic alterations associated with outcome and immunogenicity in cancers with brain metastasis. *Frontiers in immunology*, 16, 1607772.

Yang Q, et al. (2025) Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function. *Scientific reports*, 15(1), 8437.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. *Immunity*, 58(11), 2864.

Knight AD, et al. (2025) Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. *medRxiv : the preprint server for health sciences*.

Wang H, et al. (2025) Genome-Wide Association Analysis of Flavor Precursor Traits in Chengkou Mountain Chicken. *Animals : an open access journal from MDPI*, 15(12).